Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators.
Kontoghiorghes
G J
GJ
Department of Haematology, Royal Free Hospital School of Medicine, London, UK.
D000535:Aluminum / Q000506:poisoning* / Q000633:toxicity; D000818:Animals; D001711:Biotransformation; D002614:Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D000077543:Deferiprone; D015195:Drug Design; D005314:Embryonic and Fetal Development / Q000187:drug effects; D006801:Humans; D007501:Iron / Q000506:poisoning* / Q000633:toxicity; D007502:Iron Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D051379:Mice; D011041:Poisoning / Q000188:drug therapy; D011728:Pyridones / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D013329:Structure-Activity Relationship; D013810:Therapeutic Equivalency
D002614:Chelating Agents; D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D000535:Aluminum; D007501:Iron